Pipeline
From Discovery to Phase II
First-in-Class, Non-Systemic Therapies Designed to Address Limitations of Current Standards of Care
Program
Discovery
IND-enabling
Phase I
Phase II
EL-924
Program
Discovery
IND-enabling
Phase I
Phase II
EL-156
Inflammatory Bowel Disease (IBD)
Program
Discovery
IND-enabling
Phase I
Phase II
EL-787
Irritable Bowel Syndrome (IBS)&(SIBO)
Redefining metabolic treatment in obesity.
EL-924 is a first-in-class therapeutic designed to address obesity through modulation of the body’s intrinsic metabolic regulation — moving beyond traditional approaches centered on calorie restriction or appetite suppression.
Potentially addressing key limitations of current standard-of-care therapies.
Differentiation
Designed to overcome the limitations of today's therapies.
Today's standard of care
Limitations of GLP-1 / GIP therapies
Lean mass loss associated with weight reduction
Gastrointestinal tolerability limitations in a substantial subset of patients
Poor long-term adherence
EL-924
Designed to overcome prior limitations
Robust observed biological effect
Early human data suggesting favorable tolerability
Early signals suggesting preservation of lean mass during weight loss
Profile
A non-systemic, mechanistically distinct therapy.
EL-924 is designed for local gastrointestinal activity with minimal systemic exposure — enabling a differentiated profile across safety, combinability, and breadth.
Differentiated safety profile
Local activity in the proximal small intestine with minimal systemic exposure.
Combinable with existing therapies
Mechanism complements — and is distinct from — current standard of care.
Broad applicability
Designed for obesity, insulin resistance, and related metabolic conditions.
Platform Extensions:
EL-156 in IBD and EL-787 in Functional GI Disorders
Insights from EL-924’s protective coating and local epithelial interaction helped inform the development of two additional gut-directed programs:
EL-156 for inflammatory bowel disease and EL-787 for functional GI disorders, including IBS-D, SIBO-like symptoms, and bloating.
EL-156:
EL-156 — Epithelial Restoration & Barrier Integrity Therapy Addressing Core Limitations of Current IBD Therapies
Despite major advances in IBD treatment, a fundamental therapeutic gap remains: current therapies primarily target inflammation, while few directly protect the damaged intestinal epithelium and support restoration of barrier integrity.
EL-156 is a gut-localized, non-immunosuppressive epithelial restoration and barrier integrity therapy designed to form a transient protective layer over inflamed and ulcerated intestinal tissue. By shielding the damaged epithelium from harmful luminal factors, EL-156 is designed to reduce ongoing injury and create conditions that support mucosal recovery.
Across multiple preclinical colitis models, EL-156 rapidly reduced bleeding and diarrhea. Most notably, in a severe DSS colitis model in which treatment was initiated only after severe disease was established, a short 5-day course of EL-156 increased survival from approximately 30% to 80%.
These findings support the potential of EL-156 as a rapid, locally acting therapy that addresses epithelial and barrier injury from the luminal side—providing a mechanism that may complement existing biologic and immunomodulatory treatments for IBD.
EL-787: Functional GI Disorders Targeting Gut Sensitivity & Microbiota in IBS-D, SIBO & Bloating
Bloating, food-related GI symptoms, and altered bowel function are common features of functional GI disorders and can arise from complex interactions among food, the intestinal microbiota, and gut sensitivity.
EL-787 is a gut-localized therapy designed to modulate these luminal interactions and reduce abnormal gut sensitivity, addressing interconnected symptoms associated with IBS-D, SIBO-related dysfunction, bloating, and food-triggered GI discomfort.
EL-787 emerged from our work to optimize GI tolerability during nutrient diversion weight loss therapy with EL 924. Early human observations showed encouraging potential for rapid improvement of pre-existing bloating, SIBO-like symptoms, food tolerance, diarrhea, and associated GI discomfort.
Designed as a locally acting, potentially PRN oral therapy, EL-787 may provide rapid symptom relief by modulating food- and microbiota-related luminal interactions, reducing gut sensitivity, and supporting mucosal defense and barrier function.
